Caution: JavaScript execution is disabled in your browser or for this website. You may not be able to answer all questions in this survey. Please, verify your browser parameters.

ACT KM Submission Portal

Supporting Knowledge Mobilization of High-Impact Randomized Controlled Trials in Canada


Welcome to the ACT Canada submission portal for the ACT Knowledge Mobilization (KM) Award.  Your application must be submitted via this portal, emailed applications will not be accepted.  

 

Application Components:

Please complete all questions in this portal and upload a single PDF of your application.  Naming convention for the PDF should include a PI last name and project title (e.g., "Smith_ProjectTitle.pdf"). 

Please refer to the Call for Proposals (link) for detailed breakdown of section requirements and scoring.

  • Summary: 1 page.
  • Written Proposal: max 2 pages if written in English or 3 pages if written in French. 
  • Budget and justification: 1 page.
  • References, figures, or tables: (optional, max 1 page).
  • Deadline: Submitted by  Monday, April 21, 2025 at noon ET. 
    • Late submissions will not be accepted.
    • Once submitted, confirmation of receipt will be provided. If you do not hear back within 24 hours, please follow up to ensure successful delivery.

If you have any concerns or questions about this application process, please contact the Coordinating Team at ACT.Canada@phri.ca 

Thank you for your interest in the ACT Canada Consortium and for your application.  

**Application can be saved and resumed at any time by selecting "Resume Later" in the top right corner.**
(This question is mandatory)

1. Which ACT Canada Research network (link) has endorsed this application?

  • Each network can endorse a maximum of 3 applications

(This question is mandatory)
2. Please provide the KM project name and details for the high-impact randomized controlled trial (RCT).

3. Please provide details for the Principal Investigator(s) as listed in the trial protocol for this submission.

  • Principal Investigator(s) leading the application can only submit one application to this competition.
  • Full membership details, including co-applicants, can be included in the PDF.
Principal Investigator #1
Principal Investigator #2
Principal Investigator #3
(This question is mandatory)

4. Which CIHR eligible institution will hold funds for this submission?

  • This organization will ensure and report that funds were used for CIHR eligible expenses
(This question is mandatory)
5. What amount is being requested for the KM project?
Maximum $10,000 CAD
(This question is mandatory)
6. When will the KM project be completed?
ACT funding must be used by 2026/01/31
Open date/time selector
(This question is mandatory)

7. Checklist:

  • We provide this checklist for your convenience. Please ensure you include all requirements as described in the Call for Proposals (link) and check each section for completion, accuracy, and eligibility.

RCT Details: Trial must be completed by August 31, 2025. High impact, high-quality RCT that uses a form of randomization (e.g., parallel group, cluster/stepped wedge/cluster cross-over, factorial, platform).
Knowledge Mobilization: The KM project must focus on novel and impactful approaches to knowledge mobilization of the results of a completed, Canadian-led, high-impact randomized controlled trial. Non-traditional knowledge mobilization strategies are encouraged.
Endorsement: Application is endorsed by one of the 34 ACT Networks. Each ACT Network can endorse a maximum of three applications to this competition. No letter of support is required from the supporting ACT Network.
Budget: Applicants can request up to $10,000 (CAD) in direct funding. The budget adheres to the CIHR Patient Partner Compensation Guidelines (as appropriate). In-kind and matched funds are encouraged.
Timeline: The overall KM initiative/strategy may take longer to finish, but the ACT funding must be utilized by January 31, 2026. Reporting deadline is end of December, 2025.
CIHR Eligible:  Funds will be transferred to an organization eligible to hold CIHR funds; this organization will ensure and report that funds were used for CIHR eligible expenses.
Institutional Budget Review:  PDF includes the statement “I have confirmed my institution (which will hold the grant funds) has reviewed my proposed budget and deems all items to be CIHR eligible.”
Acknowledgement: The Principal Investigator(s) will acknowledge ACT Consortium partnership and funding in all related presentations and publications.
PDF: Includes trial summary, budget justification, and proposal (max. 2 pages in English, max. 3 pages in French), which includes the Knowledge Mobilization and Engagement Plan.
(This question is mandatory)

8. Submission Package PDF:

  • Please submit a single PDF with file name that includes a PI last name and project title (e.g., "Smith_ProjectTitle.pdf"). 
  • It is your responsibility to ensure that the file you upload contains all required components. 
e.g., "Smith_ProjectTitle.pdf"
 Upload file
(This question is mandatory)
9. What email address should be used for correspondence and confirmation of submission?

Once you are satisfied with your submission, please press the  [submit]  button bottom right. 

We will send an email confirming receipt of your application to the correspondence email address provided.  

Thank you for your interest in ACT Canada and for your submission.

The Accelerating Clinical Trials Consortium is generously supported through multi-year funding from the Canadian Institutes of Health Research’s Clinical Trials Fund, as part of Canada’s Biomanufacturing and Life Sciences Strategy to ensure that Canadians are well served by a national clinical trials network.

CIHR's leaf identifier - full-colour portrait version
 
Close